Key result
Emerging targeted therapies pelacarsen and olpasiran show promise for managing high Lp(a) cardiovascular risk.
Why the study?
Despite increasing recognition of the role of Lp(a) in cardiovascular pathologies for more than 50 years, there is no standardized measurement method or appropriate interventional agent.
This comprehensive review underscores the clinical importance of Lipoprotein(a) screening and the urgent need for standardized assays and specific Lp(a)-lowering therapies to mitigate cardiovascular risk.
May support Lp(a) screening in risk assessment; leaves open efficacy of targeted therapies pending RCTs.
Lipoprotein (a) (Lp(a)) attests to be of interest as a new lipoprotein target. However, Lp(a) was discovered in 1963 and since then was recognized as a low-density lipoprotein (LDL)-like lipoprotein with a structurally similar domain to plasminogen. We are increasingly recognizing the importance of Lp(a) and cardiovascular pathologies including atherosclerotic cardiovascular disease, aortic valve stenosis, heart failure, and atrial fibrillation. However, we neither have a standardized measurement method nor an appropriate agent to intervene with this old threat that we have recognized for more than 50 years. Herein, we present an up-to-date review of our knowledge about Lp(a) covering measurement methods, its associates, and summary of the currently available therapies and emerging therapeutic agents for the management of high Lp(a) in the light of recent evidence and guideline recommendations
No takes yet. Share an insight, caveat, or question.
Kayıkçıoğlu et al. (2023) conducted a review in High Lipoprotein(a). Lipid lowering therapies was evaluated. Emerging targeted therapies such as pelacarsen and olpasiran offer promising approaches for the management of high Lipoprotein(a), a recognized independent risk factor for cardiovascular disease.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: